Aktis Oncology is developing cancer radiation treatments intended to more precise and potent compared to other radiotherapies. The startup is now out of stealth with $72 million in Series A financing.
Endocyte entered its targeted radioligand therapy, Lu-PSMA-617, into a Phase III study in June following Phase II data showing more than 60 percent response rate.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The challenge with radiation and other cancer therapies is getting the right amount of treatment to the tumor and leaving healthy cells unscathed.